2025 年第 7 期 第 20 卷

心可舒胶囊联合低剂量替格瑞洛治疗不稳定型心绞痛的临床研究

Clinical study of Xinkeshu capsule combined with low-dose ticagrelor in the treatment of unstable angina pectoris

作者：王菲1徐芹2王文芝3

英文作者：Wang Fei1 Xu Qin2 Wang Wenzhi3

单位：1火箭军特色医学中心药剂科，北京100088；2中国人民解放军联勤保障部队第九六〇医院药剂科，济南250031；3山东省泰安市中心医院药剂科，泰安271000

英文单位：1Department of Pharmacy Characteristic Medical Center of Rocket Army Beijing 100088 China; 2Department of Pharmacy the 960th Hospital of the Joint Service Support Force of the Chinese People′s Liberation Army Jinan 250031 China; 3Department of Pharmacy Taian Central Hospital Shandong Province Taian 271000 China

关键词：不稳定型心绞痛；心可舒胶囊；替格瑞洛

英文关键词：Unstableanginapectoris;Xinkeshucapsule;Ticagrelor

• 摘要：

• 目的 探讨心可舒胶囊联合低剂量替格瑞洛治疗不稳定型心绞痛（UAP）的效果及安全性。方法 选取2021年3月至2024年1月在火箭军特色医学中心接受治疗的136例UAP患者，采用随机数字表法分为对照组和观察组，各68例。对照组接受阿司匹林肠溶片和低剂量替格瑞洛片的抗血小板治疗；观察组在对照组的基础上采用心可舒胶囊进行治疗。2组均治疗6个月。比较2组临床疗效、治疗前后中医证候积分和血清白细胞介素6（IL-6）、C反应蛋白（CRP）、丙二醛、谷胱甘肽过氧化物酶（GSH-Px）水平。比较2组患者出血事件、心血管事件以及药物不良反应发生情况。结果 观察组总有效率明显高于对照组［95.6%（65/68）比85.3%（58/68）］，差异有统计学意义（P=0.041）。治疗6个月后，2组患者胸痛、胸闷、心悸等积分均低于治疗前，且观察组各项中医证候积分均低于对照组（均P＜0.05）。治疗6个月后，2组血清IL-6、CRP和丙二醛水平均低于治疗前，血清GSH-Px水平均高于治疗前（均P＜0.05），且观察组治疗6个月后血清IL-6、CRP、丙二醛水平均低于对照组，血清GSH-Px水平高于对照组（均P＜0.05）。2组患者均未出现中度出血、严重出血以及心血管事件。2组患者轻度出血及不良反应发生率比较，差异均无统计学意义（均P＞0.05）。结论 心可舒胶囊联合低剂量替格瑞洛治疗UAP具有较好的临床效果，可有效改善患者体内炎症反应和氧化应激反应，且具有较好的安全性。

• Objective  To investigate the efficacy and safety of Xinkeshu capsule combined with low-dose ticagrelor in the treatment of unstable angina pectoris (UAP). Methods A total of 136 UAP patients who were treated in Characteristic Medical Center of Rocket Army from March 2021 to January 2024 were selected. According to the random number table method, they were divided into the control group and the observation group, with 68 cases in each group. The control group was treated with aspirin enteric-coated tablets and low-dose ticagrelor tablets. The observation group was treated with Xinkeshu capsule on the basis of the control group. Both groups were treated for 6 months. The clinical efficacy, traditional Chinese medicine syndrome score, serum levels of interleukin-6 (IL-6), C-reactive protein (CRP), malondialdehyde, and glutathione peroxidase (GSH-Px) before and after treatment were compared between the two groups. Bleeding events, cardiovascular events and adverse drug reactions were compared between the two groups. Results The total effective rate of the observation group was significantly higher than that of the control group ［95.6%(65/68) vs 85.3%(58/68)］(P=0.041). After 6 months of treatment, the scores of chest pain, chest tightness and palpitation in the two groups were lower than those before treatment, and the scores of traditional Chinese medicine syndromes in the observation group were lower than those in the control group (all P＜0.05). After 6 months of treatment, the serum levels of IL-6, CRP and malondialdehyde in the two groups were lower than those before treatment, and the serum level of GSH-Px was higher than that before treatment (all P＜0.05). The serum levels of IL-6, CRP and malondialdehyde in the observation group were lower than those in the control group, and the serum level of GSH-Px was higher than that in the control group (all P＜0.05). There were no moderate bleeding, severe bleeding and cardiovascular events in the two groups. There was no significant difference in the incidence of mild bleeding and adverse reactions between the two groups (both P＞0.05). Conclusion Xinkeshu capsule combined with low-dose ticagrelor has a good clinical effect in the treatment of UAP, which can effectively improve the inflammatory response and oxidative stress response in patients with good safety.